Vertex Pharmaceuticals
Logotype for Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals (VRTX) investor relations material

Vertex Pharmaceuticals Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Vertex Pharmaceuticals Inc
Jefferies Global Healthcare Conference summary17 Nov, 2026

Pipeline and revenue outlook

  • 2026 milestones include a Nov. 30 PDUFA decision for povetacicept in IgAN and DM1 phase II proof-of-concept data by year-end.

  • 2027 catalysts include Q1 interim phase III AMPLITUDE data, H1 povetacicept myasthenia gravis proof-of-concept results, and midyear phase III suzetrigine data in diabetic peripheral neuropathy.

  • 2026 non-CF revenue was projected at $500M+ from JOURNAVX and CASGEVY; PALSONIFY adds to that base, with further non-CF growth expected in 2027 alongside a solid CF outlook.

Povetacicept in IgAN

  • Interim results showed 52% proteinuria reduction at 36 weeks, >80% hematuria resolution, and 42% of patients reaching KDIGO guidelines.

  • Administration is planned once every four weeks at home via a 0.46 mL auto-injector; lower viscosity may reduce injection discomfort.

  • The Nov. 30, 2026 PDUFA remained on track; management expected a class-consistent label without IgG monitoring, citing serious infections of 0.5% in both drug and placebo arms.

  • A two-year eGFR endpoint is required in Europe and Asian markets; estimated diagnosed populations were 160,000 in the U.S., a similar number in Europe, and 1.5M–1.6M globally.

  • Management views the U.S. opportunity as a broader market-expansion opportunity; plans include a large disease-modifying field force and renal patient services modeled on CF support programs.

Inaxaplin in APOL1 kidney disease

  • Q1 2027 interim AMPLITUDE phase III data will assess eGFR slope; FDA discussions identify eGFR slope as necessary for an accelerated approval filing.

  • Inaxaplin inhibits >98% of APOL1; phase II showed 47.6% proteinuria reduction at 13 weeks, while AMPLIFIED showed 44% reduction in patients with baseline proteinuria of 0.3–0.7 g/g.

  • Management said two APOL1 variants, rather than FSGS histology, define the target population; natural-history data suggest placebo eGFR decline of 6–7 mL/min/year.

  • U.S. epidemiology estimates include 150,000 patients with two APOL1 alleles and modest-to-severe proteinuria without comorbidities, plus 100,000 with comorbidities such as type 2 diabetes.

  • Commercialization plans include physician education, genotyping initiatives, community outreach, and a likely companion diagnostic.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Vertex Pharmaceuticals earnings date

Logotype for Vertex Pharmaceuticals Inc
9th Annual Evercore ISI HealthCONx Conference1 Dec, 2026
Vertex Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Vertex Pharmaceuticals earnings date

Logotype for Vertex Pharmaceuticals Inc
9th Annual Evercore ISI HealthCONx Conference1 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Its products include KALYDECO (ivacaftor), ORKAMBI (lumacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), VX-445, and VX-659, as well as other product candidates at various stages of research, development, and commercialization. The company has collaboration agreements with CRISPR Therapeutics AG; Moderna, Inc.; CRISPR Therapeutics AG; Editas Medicine, Inc.; Frontline BioVentures; Merck & Co., Inc.; Cystic Fibrosis Foundation Therapeutics, Incorporated; Bristol-Myers Squibb Company; Altimmune, Inc.; and Tesaro, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.